KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial.

Linmar Rodríguez-Guilarte, Constanza Méndez, Antonia Reyes, Mariana Rios, Francisca Román, Daniela Moreno-Tapia, Alex Cabrera, Daniela B Rivera, Cristián Gutiérrez-Vera, Pablo A Palacios, Andrea Schilling, Sofia Aljaro, Francisca Bascur, Álvaro Rojas, Constanza Del Río, Patricio Astudillo, Carlos M Perez, Loreto Perez, Maite Oyonarte, Patricia E Fernández Vásquez, Rosa M Feijoo, Daniel Beltrán Campos, Carlos Tovar De Sousa, Andrea Castejón, Silvana Grandón, Marcela Villarroel, Pía Jara, Loreto Twele, M Angélica Domínguez, José V González-Aramundiz, María Javiera Álvarez-Figueroa, Wanqi Yang, Qianqian Xin, Leandro J Carreño, Mario Calvo, Susan M Bueno, Hernán F Peñaloza, Pablo A González, Alexis M Kalergis

Nat Commun 17(1) 407

PMID41354738
PMCIDPMC12796199
DOI10.1038/s41467-025-67102-y
发表日期2025-12-07
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:ROC 图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。
摘要

摘要

Annual vaccination is an effective strategy for preventing severe disease caused by seasonal influenza. Quadrivalent influenza vaccines (QIVs) protect against two strains of influenza A and two strains of influenza B, thereby enhancing the host antiviral neutralizing antibody response and inducing CD4+ and CD8+ T cell responses. Here, we report findings from a randomized, double-blind, active-controlled phase 3 clinical trial (NCT05431725) that includes 334 healthy adults aged 18-64 years and evaluates the humoral and cellular antiviral immune responses induced by two inactivated QIVs, Sinovac-QIV and Vaxigrip-Tetra™. The primary endpoint of the study is the specific antibody responses measured by hemagglutination inhibition (HAI) assays 28 days post-vaccination, while the secondary endpoint is virus-specific T cell responses. Both QIVs elicit significant increases in antibody titers 28 days after vaccination; Sinovac-QIV induces 9-10-fold increases in geometric mean titers, while Vaxigrip-Tetra™ elicits 7-8-fold increases (p < 0.05). Cellular immune responses using ELISPOT and supervised and unsupervised flow cytometry analyses show that both vaccines modulate the frequency of hemagglutinin-specific CD4+ and CD8+ T cell subsets, inducing distinct T cell response profiles. Although cellular analyses are evaluated in a subgroup of the cohort, the data indicate that both QIVs induce robust humoral and cellular immunity in adults, providing mechanistic insights into vaccine-induced protection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Study profile, cohort included in the study, vaccination schedule, and sample collection of enrolled subjects. A Schematic representation and sample distribution of the study. This study included 263 out of 320 immunized individuals from the cohort enrolled across five different centers in Chile: CL01 (UC Christus-Marcoleta), CL04 (CIMER), CL05 (Clínica Alemana), CL07 (Hospital de Puerto Montt), and CL08 (Universidad San Sebastián). From a total of 263 volunteers included, 131 received Vaxigrip-Tetra TM , and 132 received Sinovac-QIV. Cellular immunity was analyzed in PBMCs from a subgroup of 56 volunteers, all from center CL01 (27 received Vaxigrip-Tetra TM and 29 received Sinovac-QIV) at each time point. Samples excluded due to quality control failure correspond to PBMCs, for which the frequency of AIM + T cells was too low to allow adequate representation in the bh-SNE analysis. This is because the algorithm requires a minimum number of events to detect cellular patterns. B Timeline of the vaccination schedule and sample collection. Created in BioRender. González, P. (2025) https://BioRender.com/h4f93v9 .
非 KM Figure
Fig. 2Fig. 2. Humoral immune response against influenza before and post-immunization. Reciprocal titer of antibodies against several strains of influenza virus (A/H1N1, A/H3N3, B/Yamagata, and B/Victoria) was measured by hemagglutination inhibition assay (HAI) in subjects vaccinated with ( A ) Sinovac-QIV and with ( B ) Vaxigrip-Tetra TM . C The reciprocal titer of antibodies was compared between the two vaccines at 28 days post-immunization. The geometric mean titer of HAI antibodies against each strain was calculated by geometric mean and 95% CI. The data were transformed to Log 2 . The numbers in black correspond to pre- and post-immunization GMT, and the blue numbers correspond to the geometric mean increase, and the red numbers correspond to the geometric mean decrease. n = 131 (volunteers immunized with Vaxigrip-Tetra TM ) and n = 132 (volunteers immunized with Sinovac-QIV). A , B Statistical significance was assessed using a two-tailed paired t-test ( p < 0.0001 for all comparisons). C Data are presented as geometric mean values ± SEM. Two-tailed unpaired t-test (independent samples). p < 0.05 was considered statistically significant. Source data are provided in a Source Data file.
非 KM Figure
Fig. 3Fig. 3. Immunization with Sinovac-QIV and Vaxigrip-Tetra TM did not increase the number of IFN-γ-producing cells in response to HA. PBMCs were stimulated for 48 h with 2.5 μg/mL of HA-derived proteins from A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. The number of Spot Forming Cells (SFCs) secreting IFN-γ was quantified in PBMCs isolated from subjects vaccinated with ( A ) Sinovac-QIV and with ( B ) Vaxigrip-Tetra TM , before and after immunization. C The number of SFCs secreting IFN-γ was compared between the two vaccines at 28 days post-immunization. The data were normalized with the untreated control. Representative ELISPOT images for ( D ) Sinovac-QIV and E Vaxigrip-Tetra™ are shown, where red spots correspond to IFN-γ-secreting cells and blue spots correspond to IL-4-secreting cells: n = 27 (volunteers vaccinated with Vaxigrip-Tetra TM ) and n = 29 (volunteers vaccinated with Sinovac-QIV). Numbers above dots represent the mean. The numbers in blue represent fold increases, and the numbers in red represent fold reductions. A , B Statistical significance was assessed using a two-tailed paired t-test. C Data are presented as mean values ± SEM. Two-tailed unpaired t-test (independent samples). p < 0.05 was considered statistically significant. Source data are provided in a Source Data file.
非 KM Figure
Fig. 4Fig. 4. CD4 + AIM + T cell clustering analyses after immunization with Sinovac-QIV or Vaxigrip-Tetra TM . A Clustering analyses with the Phenograph algorithm (Euclidean distance, 350 neighbors) grouped CD4 + AIM + T cells in 29 clusters. B Relative expression levels of CD137, ICOS, CD45RA, Lag3, PD1, CCR7, CD69, CD38, OX40, and CXCR5 for each cluster were quantified and represented in a heatmap. Phenotype profile and changes in frequency of CD4 + AIM + T cell clusters following vaccination with Sinovac-QIV and Vaxigrip-Tetra TM in response to ( C ) A/H1N1, ( D ) A/H3N2, ( E ) B/Vitoria, and ( F ) B/Yamagata. n = 27 (volunteers immunized with Sinovac-QIV) and n = 23 (volunteers immunized with Vaxigrip-Tetra TM ). Numbers above dots represent the mean. For each strain, a two-way mixed-effects ANOVA was performed, followed by Holm–Šídák’s multiple comparisons test. Paired comparisons were conducted within each vaccine group (day 0 vs. day 28), and unpaired comparisons were performed between vaccine groups at day 28. p < 0.05 was considered statistically significant. Source data are provided in a Source Data file.
非 KM Figure
Fig. 5Fig. 5. CD8 + AIM + T cell clustering analyses after immunization with Sinovac-QIV and/or Vaxigrip-Tetra TM . A Clustering analyses with the Phenograph algorithm (Euclidean distance, 350 neighbors), and grouped CD8 + AIM + T cells in 21 clusters. B Relative expression levels of CD137, ICOS, CD45RA, Lag3, PD1, CCR7, CD69, CD38, OX40, and CXCR5 for each cluster were quantified and represented in a heatmap. Phenotype profile and changes in frequency of CD4 + AIM + T cell clusters following vaccination with Sinovac-QIV and Vaxigrip-Tetra TM in response to ( C ) A/H1N1, ( D ) A/H3N2, ( E ) B/Vitoria, and ( F ) B/Yamagata. Numbers above dots represent the mean. n = 26 (volunteers immunized with Sinovac-QIV) and n = 19 (volunteers immunized with Vaxigrip-Tetra TM ). Numbers above dots represent the mean. For each strain, a two-way mixed-effects ANOVA was performed, followed by Holm–Šídák’s multiple comparisons test. Paired comparisons were conducted within each vaccine group (day 0 vs. day 28), and unpaired comparisons were performed between vaccine groups at day 28. p < 0.05 was considered statistically significant. Source data are provided in a Source Data file.
非 KM Figure